You’re very welcome. You’re doing this with re
Post# of 157777
Yes, getting the specific type of cancer will be important before reaching out to the company. Many compassionate use or “Right to Try” cases depend on matching the mechanism of the drug to the cancer type, especially with something as targeted as leronlimab. Once you have that, you’ll be in a much stronger position to advocate for her.
You’re not alone in this keep me posted.

